A clinical review of focused ultrasound ablation with magnetic resonance guidance: An option for treating uterine fibroids

Gina K. Hesley, Krzysztof R. Gorny, Tara L. Henrichsen, David A Woodrum, Douglas L. Brown

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Uterine fibroids are common smooth muscle tumors, which can result in substantial symptoms affecting the quality of life of women. Whereas patients have several options available for treatment, focused ultrasound ablation is one of the least invasive treatment options outside medical therapy. Magnetic resonance-guided focused ultrasound (MRgFUS) ablation combines therapy delivered by an ultrasound transducer with imaging, guidance for therapy, and thermal feedback provided by magnetic resonance imaging. In 2004, the MRgFUS system ExAblate 2000 (InSightec, Haifa, Israel) was approved by the United States Food and Drug Administration for clinical treatments of uterine fibroids. Since its approval, our institution has performed more than 140 treatments. This paper provides an overview of our site's clinical experience with MRgFUS, including a brief description of the treatment system, pertinent features to review on screening magnetic resonance imaging, how the procedure is performed, and risks and benefits of the treatment. Some potential clinical applications of the technology are also briefly reviewed.

Original languageEnglish (US)
Pages (from-to)131-139
Number of pages9
JournalUltrasound Quarterly
Volume24
Issue number2
DOIs
StatePublished - Jun 2008

Fingerprint

Leiomyoma
Magnetic Resonance Spectroscopy
Therapeutics
Magnetic Resonance Imaging
Smooth Muscle Tumor
Israel
United States Food and Drug Administration
Transducers
Hot Temperature
Quality of Life
Technology

Keywords

  • Ablation
  • Focused ultrasound
  • MRI
  • Uterine fibroids

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

A clinical review of focused ultrasound ablation with magnetic resonance guidance : An option for treating uterine fibroids. / Hesley, Gina K.; Gorny, Krzysztof R.; Henrichsen, Tara L.; Woodrum, David A; Brown, Douglas L.

In: Ultrasound Quarterly, Vol. 24, No. 2, 06.2008, p. 131-139.

Research output: Contribution to journalArticle

Hesley, Gina K. ; Gorny, Krzysztof R. ; Henrichsen, Tara L. ; Woodrum, David A ; Brown, Douglas L. / A clinical review of focused ultrasound ablation with magnetic resonance guidance : An option for treating uterine fibroids. In: Ultrasound Quarterly. 2008 ; Vol. 24, No. 2. pp. 131-139.
@article{45472e28472448788fffd455f3aa4dd0,
title = "A clinical review of focused ultrasound ablation with magnetic resonance guidance: An option for treating uterine fibroids",
abstract = "Uterine fibroids are common smooth muscle tumors, which can result in substantial symptoms affecting the quality of life of women. Whereas patients have several options available for treatment, focused ultrasound ablation is one of the least invasive treatment options outside medical therapy. Magnetic resonance-guided focused ultrasound (MRgFUS) ablation combines therapy delivered by an ultrasound transducer with imaging, guidance for therapy, and thermal feedback provided by magnetic resonance imaging. In 2004, the MRgFUS system ExAblate 2000 (InSightec, Haifa, Israel) was approved by the United States Food and Drug Administration for clinical treatments of uterine fibroids. Since its approval, our institution has performed more than 140 treatments. This paper provides an overview of our site's clinical experience with MRgFUS, including a brief description of the treatment system, pertinent features to review on screening magnetic resonance imaging, how the procedure is performed, and risks and benefits of the treatment. Some potential clinical applications of the technology are also briefly reviewed.",
keywords = "Ablation, Focused ultrasound, MRI, Uterine fibroids",
author = "Hesley, {Gina K.} and Gorny, {Krzysztof R.} and Henrichsen, {Tara L.} and Woodrum, {David A} and Brown, {Douglas L.}",
year = "2008",
month = "6",
doi = "10.1097/RUQ.0b013e31817c5e0c",
language = "English (US)",
volume = "24",
pages = "131--139",
journal = "Ultrasound Quarterly",
issn = "0894-8771",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A clinical review of focused ultrasound ablation with magnetic resonance guidance

T2 - An option for treating uterine fibroids

AU - Hesley, Gina K.

AU - Gorny, Krzysztof R.

AU - Henrichsen, Tara L.

AU - Woodrum, David A

AU - Brown, Douglas L.

PY - 2008/6

Y1 - 2008/6

N2 - Uterine fibroids are common smooth muscle tumors, which can result in substantial symptoms affecting the quality of life of women. Whereas patients have several options available for treatment, focused ultrasound ablation is one of the least invasive treatment options outside medical therapy. Magnetic resonance-guided focused ultrasound (MRgFUS) ablation combines therapy delivered by an ultrasound transducer with imaging, guidance for therapy, and thermal feedback provided by magnetic resonance imaging. In 2004, the MRgFUS system ExAblate 2000 (InSightec, Haifa, Israel) was approved by the United States Food and Drug Administration for clinical treatments of uterine fibroids. Since its approval, our institution has performed more than 140 treatments. This paper provides an overview of our site's clinical experience with MRgFUS, including a brief description of the treatment system, pertinent features to review on screening magnetic resonance imaging, how the procedure is performed, and risks and benefits of the treatment. Some potential clinical applications of the technology are also briefly reviewed.

AB - Uterine fibroids are common smooth muscle tumors, which can result in substantial symptoms affecting the quality of life of women. Whereas patients have several options available for treatment, focused ultrasound ablation is one of the least invasive treatment options outside medical therapy. Magnetic resonance-guided focused ultrasound (MRgFUS) ablation combines therapy delivered by an ultrasound transducer with imaging, guidance for therapy, and thermal feedback provided by magnetic resonance imaging. In 2004, the MRgFUS system ExAblate 2000 (InSightec, Haifa, Israel) was approved by the United States Food and Drug Administration for clinical treatments of uterine fibroids. Since its approval, our institution has performed more than 140 treatments. This paper provides an overview of our site's clinical experience with MRgFUS, including a brief description of the treatment system, pertinent features to review on screening magnetic resonance imaging, how the procedure is performed, and risks and benefits of the treatment. Some potential clinical applications of the technology are also briefly reviewed.

KW - Ablation

KW - Focused ultrasound

KW - MRI

KW - Uterine fibroids

UR - http://www.scopus.com/inward/record.url?scp=48549097109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48549097109&partnerID=8YFLogxK

U2 - 10.1097/RUQ.0b013e31817c5e0c

DO - 10.1097/RUQ.0b013e31817c5e0c

M3 - Article

C2 - 18528271

AN - SCOPUS:48549097109

VL - 24

SP - 131

EP - 139

JO - Ultrasound Quarterly

JF - Ultrasound Quarterly

SN - 0894-8771

IS - 2

ER -